BTIG affirms Juno Therapeutics Inc. (Nasdaq: JUNO) at Neutral after the company announced that the ROCKET Study had been voluntarily ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE